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In silico identification of MAPK14-
related lncRNAs and assessment 
of their expression in breast cancer 
samples
Sepideh Dashti1, Zahra taherian-esfahani1, Vahid Kholghi-oskooei2,3, Rezvan noroozi4, 
Sharam Arsang-Jang5, Soudeh Ghafouri-fard1 ✉ & Mohammad taheri6 ✉
Mitogen-activated protein kinase (MAP kinase) pathways participate in regulation of several cellular 
processes involved in breast carcinogenesis. A number of non-coding RNAs including both microRNAs 
(miRNAs) and long non-coding RNAs (lncRNAs) regulate or being regulated by MAPKs. We performed 
an in-silico method for identification of MAPKs with high number of interactions with miRNAs and 
lncRNAs. Bioinformatics approaches revealed that MAPK14 ranked first among MAPKs. Subsequently, 
we identified miRNAs and lncRNAs that were predicted to be associated with MAPK14. Finally, we 
selected four lncRNAs with higher predicted scores (NORAD, HCG11, ZNRD1ASP and TTN-AS1) and 
assessed their expression in 80 breast cancer tissues and their adjacent non-cancerous tissues (ANCTs). 
Expressions of HCG11 and ZNRD1ASP were lower in tumoral tissues compared with ANCTs (P values < 
0.0001). However, expression levels of MAPK14 and NORAD were not significantly different between 
breast cancer tissues and ANCTs. A significant association was detected between expression of HCG11 
and estrogen receptor (ER) status in a way that tumors with up-regulation of this lncRNA were mostly 
ER negative (P value = 0.04). Expressions of ZNRD1ASP and HCG11 were associated with menopause 
age and breast feeding duration respectively (P values = 0.02 and 0.04 respectively). There was a 
trend towards association between ZNRD1ASP expression and patients’ age of cancer diagnosis. 
Finally, we detected a trend toward association between expression of NORAD and history of hormone 
replacement therapy (P value = 0.06). Expression of MAPK14 was significantly higher in grade 1 tumors 
compared with grade 2 tumors (P value = 0.02). Consequently, the current study provides evidences for 
association between lncRNA expressions and reproductive factors or tumor features.
Mitogen-activated protein kinase (MAP kinase) pathway convey and intensify cellular messages participated 
in the cell proliferation. Consequently, this pathway determines cancer cell proliferation, malignant behavior of 
tumors and patients’ outcome in breast cancer1. Experiments have shown over-expression of MAP kinase in a 
significant percentage of breast tumors express compared with the adjacent benign tissues1. Moreover, somatic 
mutations in breast cancer tissues which resulted in dysregulation of MAPK pathways have induced immune 
escape associated with poor patients’ outcome2. Notably, immunotherapeutic approaches against MAPK signal-
ing have resulted in favorable results2. Several long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have 
been shown to regulate MAPK pathway3. Among lncRNAs with fundamental roles in carcinogenesis are those 
acting as decoys for miRNAs to control transcription of coding genes by competing endogenous RNAs (ceR-
NAs)4. Some of these ceRNAs have been shown to enhance breast cancer evolution through alteration of MAPK 
signaling5 or other routes6. Based on the importance of MAPK signaling in breast cancer pathogenesis1 and 
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availability of MAPK-targeting therapies2, identification of regulatory mechanisms of this pathway has practical 
significance. The interference between ceRNAs via common miRNAs characterizes a new level of gene regulation 
that participates in the evolution of human malignancies. Such interferences can be anticipated according to the 
intersection of miRNA-binding sites7.
In the present investigation, we aimed at identification of MAPK-related lncRNAs with putative ceRNA func-
tion. Through an in silico approach, we detected MAPK14 as the most interacting RNA with miRNAs and lncR-
NAs. Consequently, we focused on this gene to identify the lncRNAs with putative interaction with it. Finally, we 
assessed expression of MAPK14-related lncRNAs in breast cancer samples and adjacent non-cancerous tissues 
(ANCTs).
Methods
In silico analyses. The total list of MAPK pathway genes were retrieved from HGNC database (https://www.
genenames.org/data/genegroup/#!/group/652). The list of miRNAs identified in Homo sapiens was downloaded 
from Mirtarbase (http://mirtarbase.mbc.nctu.edu.tw/php/index.php) and miRNA-mRNA relationship was 
evaluated using this tool (based on the experimentally validated miRNA-mRNA relationship using Reporter 
assay and Western blotting techniques). miRNA-mRNA relationships with weak evidences were filtered. From 
the obtained list of miRNA-mRNA relationship with strong evidence, those associated with MAPK genes were 
selected. Subsequently, lncBase v2 (http://carolina.imis.athena-innovation.gr/diana_tools/web/index.php?r=l-
ncbasev2%2Findex-experimental) was used for assessment of miRNA-lncRNA associations. The identified miR-
NAs from the previous step were assessed in lncBase v2 and the associated lncRNAs were retrieved. Scores>0.8 
was used as the threshold. The miRNA-mRNA relationship was evaluated using Mirtarbase (http://mirtarbase.
mbc.nctu.edu.tw/php/index.php) which is tool which reports these interactions based on the experimentally 
validated miRNA-mRNA relationship using Reporter assay and Western blotting techniques. The previous steps 
provided the list of lncRNA-miRNA-mRNA triplets to find the lncRNAs with potential sponging activities. Next, 
Expression Atlas8 data was used to identify MAPK genes with differential expression in breast cancer tissues vs. 
normal tissues. Expression of the previously identified lncRNAs has been assessed in Expression Atlas as well. 
Finally, Co-lncRNA (http://bio-bigdata.hrbmu.edu.cn/Co-LncRNA/) tool was applied to select lncRNAs which 
co-express with MAPK14 in breast tissues (Fig. 1).
Patients. In the current project, we enrolled 80 female breast cancer patients aged between 36 and 60 
(mean ± (SD) age: 49.59 ± 4.74). Malignant tissues and their corresponding ANCTs were obtained during sur-
gery, promptly transferred in liquid Nitrogen to Genetic laboratory for gene expression analyses. All samples 
were also assessed by a pathologist to verify the diagnosis. Malignant samples included seven invasive lobular 
carcinomas, one papillary carcinoma, one ductal carcinoma in situ and 71 invasive ductal carcinomas. Patients 
were recruited from Farmanieh and Sina Hospitals during 2016–2018. All patients signed inform consent forms. 
The study protocol was approved by the Ethical Committee of Shahid Beheshti University of Medical Sciences.
Expression analysis. RNA was extracted from all samples using the Hybrid-R 100 preps (GeneAll, Seoul, 
South Korea) according to the instructions. RNA samples were treated with DNAse I (Thermo SCIENTIFIC, 
Vilnius, Lithuania) to eliminate DNA contamination. Afterward, the RNA quantity and quality was assessed and 
cDNA was made from extracted RNA using Solis BioDyne kit (Estonia). Relative expressions of MAPK14 and the 
associated lncRNAs were quantified in all samples using RealQ Plus Master Mix Green (AMPLICON, Odense, 
Figure 1. The flowchart of in silico assays to find MAPK14-associtaed lncRNAs with putative miRNA-sponging 
activities.
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Denmark). B2M gene was used as normalizer. Quantitative real time PCR was executed in the rotor gene 6000 
Corbett Real-Time PCR System in duplicate. The nucleotide sequences of primers are presented in Table 1.
Statistical analyses. The significance of difference in mean values of transcript quantities between two 





























Tag Gene family description
Interaction 
number
MAPK14 6876 6p21.31 MAPK Mitogen-activated protein kinases 69
RAF1 9829 3p25.2 MAP3K Mitogen-activated protein kinase kinase kinases 64
MAPK1 6871 22q11.22 MAPK Mitogen-activated protein kinases 61
MAP2K1 6840 15q22.31 MAP2K Mitogen-activated protein kinase kinases 54
MAPK9 6886 5q35.3 MAPK Mitogen-activated protein kinases 53
MAP4K4 6866 2q11.2 MAP4K Mitogen-activated protein kinase kinase kinase kinases 21
MAP3K9 6861 14q24.2 MAP3K Mitogen-activated protein kinase kinase kinases 21
MAP3K2 6854 2q14.3 MAP3K Mitogen-activated protein kinase kinase kinases 20
MAP3K12 6851 12q13.13 MAP3K Mitogen-activated protein kinase kinase kinases 19
MAP3K11 6850 11q13.1 MAP3K Mitogen-activated protein kinase kinase kinases 16
MAP2K4 6844 17p12 MAP2K Mitogen-activated protein kinase kinases 15
MAPK3 6877 16p11.2 MAPK Mitogen-activated protein kinases 15
MAPK7 6880 17p11.2 MAPK Mitogen-activated protein kinases 15
MAP3K5 6857 6q23.3 MAP3K Mitogen-activated protein kinase kinase kinases 15
BRAF 1097 7q34 MAP3K Mitogen-activated protein kinase kinase kinases 14
MAP3K8 6860 10p11.23 MAP3K Mitogen-activated protein kinase kinase kinases 12
MAPK8 6881 10q11.22 MAPK Mitogen-activated protein kinases 12
RPS6KA4 10433 11q13.1 MAPKAPK Mitogen-activated protein kinase-activated protein kinases 11
MAP2K3 6843 17p11.2 MAP2K Mitogen-activated protein kinase kinases 8
RPS6KA1 10430 1p36.11 MAPKAPK Mitogen-activated protein kinase-activated protein kinases 8
MAP3K14 6853 17q21.31 MAP3K Mitogen-activated protein kinase kinase kinases 7
MAP2K6 6846 17q24.3 MAP2K Mitogen-activated protein kinase kinases 4
MAP3K10 6849 19q13.2 MAP3K Mitogen-activated protein kinase kinase kinases 4
RPS6KA5 10434 14q32.11 MAPKAPK Mitogen-activated protein kinase-activated protein kinases 3
MAP3K4 6856 6q26 MAP3K Mitogen-activated protein kinase kinase kinases 3
RPS6KA3 10432 Xp22.12 MAPKAPK Mitogen-activated protein kinase-activated protein kinases 3
MAPK11 6873 22q13.33 MAPK Mitogen-activated protein kinases 2
MAPK13 6875 6p21.31 MAPK Mitogen-activated protein kinases 2
MAP3K7 6859 6q15 MAP3K Mitogen-activated protein kinase kinase kinases 2
MAP4K3 6865 2p22.1 MAP4K Mitogen-activated protein kinase kinase kinase kinases 2
MAP2K7 6847 19p13.2 MAP2K Mitogen-activated protein kinase kinases 1
Table 2. The potential lncRNA-miRNA-MAPK genes interaction based on our study design.
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assumed for parameters with 4000 iteration and 2000 burn-outs. The 95% Highest density interval (HDI) was 
calculated based on the Bayesian approach. The P values were estimated from frequentist methods using quantile 
regression and mixed effects models. The ‘quantreg’, ‘ggplot2’, and ‘brms’ packages were used in R 3.5.2 environ-
ment. The association between tumor features and transcript levels of genes was evaluated using Chi-square test 
or Fisher exact test where appropriate using the Statistical Package for the Social Sciences (SPSS) v.18.0 (SPSS Inc., 
Chicago, IL). The significance of alteration between mean values of transcripts between discrete groups of patients 
was appraised using Tukey’s honest significance test. The correlation between transcript levels of genes was digni-
fied using the regression model. For all statistical tests, the level of significance was set at P < 0.05.
Results
In silico assays. There were a total 60 MAPK genes in HGNC database. These genes were assessed by 
Mirtarbase and lncBase to find miRNA and lncRNA associations. Table 2 shows the potential lncRNA-miR-
NA-MAPK genes interaction based on our study design. As MAPK14 was found to have the greatest number of 
interactions with miRNAs and lncRNAs, subsequent steps were performed on this gene.
We further listed miRNAs that were predicted to have associations with MAPK14 and listed the associated 
lncRNAs (Table 3). Co-expression analysis using GEPIA and Co-LncRNA tools revealed that NORAD, HCG11, 
ZNRD1ASP and TTN-AS1 lncRNAs co-express with MAPK14 in breast tissues. Consequently, we selected these 
four lncRNAs for expression analysis.
General data of patients. General demographic and clinical features of enrolled patients are summarized 
in Table 4.
Expression assays. A total of 80 breast cancer samples and 80 ANCTs were assessed. We could not detect 
expression of TTN-AS1 in any of malignant or non-malignant tissues, so this gene was excluded from further 
steps. Expression levels of MAPK14 and NORAD were not significantly different between breast cancer tissues 
and ANCTs. Expressions of HCG11 and ZNRD1ASP were lower in tumoral tissues compared with ANCTs (P 
values < 0.0001). Figure 2 and Table 5 show the results of expression analysis.
To further verify our results, we used ENCORI/Starbase v2 database to validate our findings in 1104 can-
cer and 113 normal samples from the TCGA project. Figure 3 shows that both HCG11 and ZNRD1ASP are 
down-regulated in breast cancer tissues from TCGA database.
Associations between expression levels of genes and patients’ features. A significant association 
was detected between expression of HCG11 and ER status in a way that tumors with up-regulation of this lncRNA 
were mostly ER negative (P value = 0.04). Besides, expressions of ZNRD1ASP and HCG11 were associated with 
menopause age and breast feeding duration respectively (P values = 0.02 and 0.04 respectively). Moreover, there 
was a trend towards association between ZNRD1ASP expression and patients age of cancer diagnosis in a way that 
expression of this lncRNA tended to be up-regulated in tumor samples from pre-menopause patients compared 
with their paired ANCTs (P value = 0.06). Finally, we detected a trend toward association between expression of 
NORAD and history of hormone replacement therapy (P value = 0.06). Table 6 and Fig. 4 summarize the results 
of association analysis between expression of genes and patients’ data.
We also compared expression of genes among distinct categories of tumor tissues (Table 7). Expression of 
MAPK14 was significantly higher in grade 1 tumors compared with grade 2 tumors (P value = 0.02). No other 
significant difference was detected in expression of genes among distinct categories of tumors.
mRNA coding gene miRNA lncRNA
MAPK14 hsa-miR-27a-3p C1orf132, DLX6-AS1, KCNQ1OT1, LINC00662, MIR4458HG, NEAT1, RASSF8-AS1, SNHG14, TOB1-AS1, TTN-AS1, ZNRD1-AS1
HGNC ID:6876 hsa-miR-17-5p LINC00116, LINC00657 (NORAD), PWAR6, SNHG14, XIST, C1orf132, TMEM161B-AS1, HCG11
Chromosome:6p21.31 hsa-miR-155-5p LINC00657 (NORAD), XIST
Gene Family Tag: MAPK
hsa-miR-34a-5p EMX2OS, KCNQ1OT1, LINC00662, NEAT1, XIST
hsa-miR-24-3p GABPB1-AS1, LINC00662, LINC01094, NEAT1
hsa-miR-199a-3p KCNQ1OT1, TUG1, XIST
hsa-miR-141-3p DNM3OS, KCNQ1OT1
Gene family hsa-miR-125b-5p C1orf132, ERC2-IT1, GLIDR, KCNQ1OT1, KRTAP5-AS1, MEG3, SRRM2-AS1, STX16-NPEPL1
description: descriptionMitogen-
activated protein kinases
hsa-miR-106a-5p GABPB1-AS1, HCG11, LINC00116, NEAT1, XIST
hsa-miR-125a-5p C1orf132, ERC2-IT1, KCNQ1OT1, KRTAP5-AS1, MEG3, SRRM2-AS1, STX16-NPEPL1
hsa-miR-124-3p TTTY15, TMEM147-AS1, STXBP5-AS1, NEAT1, LINC00643, ERVK13-1, KCNQ1OT1
hsa-miR-200a-3p XIST, KCNQ1OT1, DNM3OS, NEAT1
hsa-miR-214-3p MIA-RAB4B, KCNQ1OT1, C1RL-AS1
Table 3. LncRNA-miRNA-MAPK14 triplet (Potential Competing Endogenous Triplet).
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Correlations between expression levels of genes. A significant correlation was found between expres-
sion levels of NORAD and MAPK14 in tumor tissues but not in ANCTs. There were several other pairwise corre-
lations between expression of genes in these sets of samples (Fig. 5).
Discussion
In the present project, we evaluated expression of MAPK14 and four associated lncRNAs in breast cancer tissues 
and ANCTs. The selection of MAPK14 was based on an in silico method. In silico studies have high chances of 
false positive predictions, but they are cost-benefit methods to obtain an overview of a subject before designing 
expensive high throughput experiments. In order to decrease chance of false positive results, we paid attention to 
adjusted p-values throughout the whole process and chose an FDR adjusted p-value (or q-value) lower than 0.05 
as our cut off criteria.
Few previous studies have assessed the ceRNA network in breast cancer. For instance, Gao et al. have retrieved 
expression profiles of mRNAs, lncRNAs and miRNAs in invasive breast cancer from the TCGA database. They 
used miRcode online software to predict the interaction between lncRNAs and miRNAs. Moreover, they used 
TargetScan, miRDB and miRTarBase to obtain the target mRNAs of miRNAs. Assessment pf TCGA data led to 
identification of differential expression (DE) of 1059 lncRNAs, 86 miRNAs, and 2138 mRNAs between invasive 
breast cancer samples and normal samples. Subsequently, they construct an abnormal lncRNA-miRNA-mRNA 
ceRNA network for invasive breast cancer, consisting of 90 DElncRNAs, 18 DEmiRNAs and 26 DEmRNAs. 
According to the ceRNA network, they reported that the LINC00466-Hsa-mir-204- NTRK2 LINC00466-hsa-mir-
204-NTRK2 axis was present in the RNAs that were correlated with patients’ outcome9. Their in silico methods 
were similar to the applied method in the current study. Yet, we focused on one mRNA coding gene (MAPK14) 
instead of whole transcripts. We also assessed expression of the identified genes in our cohort of patients. Le et 
al. have used the weighted gene co-expression network analysis to the available microarray mRNA and lncRNA 
Parameters Values
Age (mean ± SD (range)) 52.82 ± 13.41 (29–84)
Menarche age (mean ± SD (range)) 13.13 ± 1.48 (10–18)
Menopause age (mean ± SD (range)) 49.59 ± 4.74 (38–60)
First pregnancy age (mean ± SD (range)) 21.35 ± 4.97 (14–37)






























Table 4. General demographic and clinical features of enrolled patients (SD: standard deviation).
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expression data of triple negative breast cancer (TNBC) patients. They performed functional enrichment on 
the module that was mostly associated with Ki-67 status (Turquoise module). They also established the ceRNA 
network. Using this model, they have recognized correlation between two mRNAs (RAD51AP1 and TYMS) and 
overall survival in TNBC. Their results indicated that TNBC-specific mRNA and lncRNAs might form a complex 
ceRNA network which can be a putative therapeutic target for TNBC10. The main difference between this article 
and our work is inclusion of only a certain type of breast cancer in the mentioned study and assessment of the 
whole transcriptome.
MAPK14 codes for α subunit of p38 MAPK. This subunit is the prototypic component of the p38 MAPK 
proteins that has been initially recognized as a tyrosine phosphorylated protein in triggered immune cell mac-
rophages. In addition, MAPK14 regulates production of a number of cytokines including TNF-α11,12. Notably, 
MAPK14 has an essential role in induction of cell migration and epithelial-to-mesenchymal transition (EMT) in 
breast cancer cells through cooperation with TGF-β13. The observed similar levels of MAPK14 between malig-
nant tissues and ANCTs is in line with the previous finding that paracrine messages from tumor cells enhance 
the expression of nuclear EMT‐transcription factors in neighboring fibroblasts leading to over-expression of 
EMT associated genes in tumor-adjacent tissues14. However, some evidences point to a tumor suppressive role 
of MAPK14 in breast cancer. For instance, the observed enhanced MAPK14 phosphorylation in Wip1-knockout 
Figure 2. Box-Scatter plot of the expression data (qPCR) of the lncRNAs in tumor tissues vs. ANCTs.
Gene




deviation Effect Size P-valueb 95% HDIcTumoral tissues ANCTs
NORAD −3.869 ± 0.19 −4.104 ± 0.24 0.142 1.84 0.078 0.955 [−0.27, 0.57]
HCG11 −16.903 ± 0.17 −6.476 ± 0.22 −10.047 2.43 −4.211 <0.0001 [−10.68, −9.41]
ZNRD1ASP −16.069 ± 0.19 −6.579 ± 0.22 −9.36 2.31 −4.09 <0.0001 [−9.91, −8.84]
MAPK14 −3.524 ± 0.2 −3.483 ± 0.19 −0.015 1.64 −0.01 0.783 [−0.4, 0.37]
Table 5. Bayesian t test for comparison of the relative expression of genes between two paired groups  
(a:Tumoral tissues-ANCTs; b:computed from frequentist method; c:95% Highest Density Interval).
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mice has been associated with lower breast tumor formation15. On the other hand, treatment of cancer cell lines 
with a certain MAPK14 inhibitor has diminished tumorigenic potential in animal models of breast cancer16. 
Notably, we detected higher levels of MAPK14 in grade 1 tumors compared with grade 2 tumors. Taken together, 
one could speculate different roles for MAPK14 in each step of breast tumorigenesis. Such distinct roles have also 
been proposed for TGF-β (a partner of MAPK14). While in early phases of breast cancer TGF- β suppresses cell 
cycle transition and enhances cell apoptosis, in late phases, this cytokine is associated with augmented tumor 
progression, greater cell motility and malignant behavior of tumor cells17.
We reported lower expression of HCG11 in tumoral tissues compared with ANCTs. We also detected a sig-
nificant association between expression of HCG11 and ER status in a way that tumors with up-regulation of 
this lncRNA were mostly ER negative. Liu et al. have previously shown associations between up-regulation of 
HCG11 and poor breast cancer outcome. However, they did not report total expression changes between tumoral 
and non-tumoral tissues. Besides, they reported association between expression of this lncRNA and ER status18. 
Consistent with our results, this lncRNA has been previously shown to be down-regulated in prostate cancer cells 
and tissues19. Forced overexpression of HCG11 in prostate cancer cells has suppressed cell proliferation, invasion 
and migration, while enhanced cell apoptosis by regulating miR‐543 expression. Besides, this lncRNA suppresses 
PI3K/AKT signaling pathway to inhibit progression of prostate cancer20. miR-543 has an inhibitory role on cell 
proliferation and cell cycle transition in breast cancer through modulation of ERK/MAPK21. Thus, the functional 
role of HCG11 in breast cancer might be mediated through this miRNA.
Moreover, in line with our observation, Zhang et al. have demonstrated HCG11 as an androgen-responsive 
lncRNA19. Moreover, through assessment of NONCODE data, they have detected over-expression of this lncRNA 
in endocrine-associated tissues such as ovary, breast and prostate, signifying its role in control of tumor evolu-
tion in these tissues19. Consistent with the proposed role for this lncRNA in endocrine-associated functions, we 
detected associations between its expression and breast feeding duration. Notably, the ceRNA network depicted 
by in silico assessments has shown participation of HCG11 in developmental processes, differentiation, gene 
expression and angiogenesis19. Thus, down-regulation of this lncRNA in tumoral tissues might be associated with 
decreased differentiation state or increased angiogenic potential.
Expression of ZNRD1ASP was lower in tumoral tissues compared with ANCTs. Besides, expression of 
ZNRD1ASP was associated with menopause age. Moreover, there was a trend towards association between 
ZNRD1ASP expression and patients’ age of cancer diagnosis in a way that expression of this lncRNA tended to be 
up-regulated in tumor samples from pre-menopause patients compared with their paired ANCTs. This lncRNA 
is transcribed from the antisense strand of Zinc ribbon domain containing 1 (ZNRD1) and negatively regulates 
expression of the sense transcript22. Previous studies have shown over-expression of ZNRD1ASP in lung can-
cer22. Moreover, single nucleotide polymorphisms (SNPs) within ZNRD1ASP modulate risk of several human 
cancers22,23.
We also reported a trend toward association between expression of NORAD and history of hormone replace-
ment therapy. This lncRNA participates in the construction of a topoisomerase complex which maintains genome 
stability24. Its over-expression in breast cancer has been associated with poor patients’ survival18. Consistent with 
our data, Liu et al. did not detect any associations between its expression and ER, PR and HER2 status18.
Although in silico studies have shown co-expression of MAPK14 with the selected lncRNAs, we could not 
detect significant correlations between expression levels of lncRNAs and MAPK14 except for one case. Such lack 
Figure 3. Analysis of ENCORI/Starbase v2 database showing down-regulation of HCG11 and ZNRD1ASP in 
breast cancer tissues of TCGA project.
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of correlation might be explained by the high level of MAPK14 expression and low levels of lncRNAs expres-
sions. MAPK14 has been previously shown to be universally expressed generally at high levels25. So its levels 
of expression are expected to be very different from lncRNAs which might conceal or dilute the expected cor-
relations. Previous studies have indicated that alterations in the ceRNA transcript levels should be adequately 
enormous to either conquer or decrease the miRNA effect on opposing ceRNAs26. Meanwhile, the observed 
correlations between expression levels of NORAD and MAPK14 in tumor tissues in spite of lack of correlation 































Age 0.92 0.66 0.06 0.14
Pre-menopause 22 (53.7%) 19 (46.3%) 21(51.2%) 20 (48.8%) 26 (61.9%) 16 (38.1%) 19 (45.2%) 23 (54.8%)
Post-menopause 20 (52.6%) 18 (47.4%) 17 (45.9%) 20 (54.1%) 15 (40.5%) 22 (59.5%) 24 (61.5%) 15 (38.5%)
Stage 0.44 0.66 0.32 0.9
1 11 (52.4%) 10 (47.6%) 9 (45%) 11 (55%) 10 (47.6%) 11 (52.4%) 10 (47.6%) 11 (52.4%)
2 11 (47.8%) 12 (52.2%) 9 (40.9%) 13 (59.1%) 11 (47.8%) 12 (52.2%) 12 (50%) 12 (50%)
3 17 (68%) 8 (32%) 15 (57.7%) 11 (42.3%) 18 (69.2%) 8 (30.8%) 15 (57.7%) 11 (42.3%)
4 2 (40%) 3 (60%) 3 (60%) 2 (40%) 2 (40%) 3 (60%) 3 (60%) 2 (40%)
Histological Grade 0.84 0.49 0.25 0.91
1 6 (54.5%) 5 (45.5%) 4 (33.3%) 8 (66.7%) 9 (69.2%) 4 (30.8%) 7 (53.8%) 6 (46.2%)
2 21 (55.3%) 17 (44.7%) 19 (51.4%) 18 (48.6%) 21 (56.8%) 16 (43.2%) 22 (57.9%) 16 (42.1%)
3 10 (47.6%) 11 (52.4%) 11 (55%) 9 (45%) 8 (40%) 12 (60%) 11 (52.4%) 10 (47.6%)
Mitotic Rate 0.51 0.73 0.35 0.49
1 14 (51.9%) 13 (48.1%) 12 (46.2%) 14 (53.8%) 17 (60.7%) 11 (39.3%) 15 (53.6%) 13 (46.4%)
2 16 (55.2%) 13 (44.8%) 16 (57.1%) 12 (42.9%) 13 (48.1%) 14 (51.9%) 19 (65.5%) 10 (34.5%)
3 3 (33.3%) 6 (66.7%) 4 (44.4%) 5 (55.6%) 3 (33.3%) 6 (66.7%) 4 (44.4%) 5 (55.6%)
Tumor size 0.53 1 0.9 0.6
<2 10 (47.6%) 11 (52.4%) 10 (47.6%) 11 (52.4%) 13 (59.1%) 9 (40.9%) 12 (54.5%) 10 (45.5%)
2–5 30 (61.2%) 19 (38.8%) 24 (50%) 24 (50%) 26 (53.1%) 23 (46.9%) 26 (52%) 24 (48%)
>5 1 (50%) 1 (50%) 1 (50%) 1 (50%) 1 (50%) 1 (50%) 2 (100%) 0 (0%)
ER status 0.56 0.04 0.49 0.3
Positive 32 (55.2%) 26 (44.8%) 24 (41.4%) 34 (58.6%) 29 (50%) 29 (50%) 31 (51.7%) 29 (48.3%)
Negative 7 (46.7%) 8 (53.3%) 11 (73.3%) 4 (26.7%) 9 (60%) 6 (40%) 10 (66.7%) 5 (33.3%)
PR status 0.73 0.19 0.45 0.83
Positive 29 (54.7%) 24 (45.3%) 23 (43.4%) 30 (56.6%) 27 (50.9%) 26 (49.1%) 29 (52.7%) 26 (47.3%)
Negative 9 (50%) 9 (50%) 11 (61.1%) 7 (38.9%) 11 (61.1%) 7 (38.9%) 10 (55.6%) 8 (44.4%)
Her2 status 0.15 0.37 0.2 0.39
Positive 5 (35.7%) 9 (64.3%) 8 (61.5%) 5 (38.5%) 4 (33.3%) 8 (66.7%) 9 (64.3%) 5 (35.7%)
Negative 33 (56.9%) 25 (43.1%) 27 (45.8%) 32 (54.2%) 34 (56.7%) 26 (43.3%) 31 (51.7%) 29 (48.3%)
Menarche age 0.01 0.7 0.57 0.24
10 to 12 years 17 (68%) 8 (32%) 13 (52%) 12 (48%) 15 (60%) 10 (40%) 10 (40%) 15 (60%)
13 to 15 years 21 (45.7%) 25 (54.3%) 20 (44.4%) 25 (55.6%) 21 (46.7%) 24 (53.3%) 28 (59.6%) 19 (40.4%)
16 to 18 years 0 (0%) 4 (100%) 3 (60%) 2 (40%) 3 (60%) 2 (40%) 3 (60%) 2 (40%)
Menopause age 0.63 0.88 0.02 1
> 50 years 12 (48%) 13 (52%) 10 (43.5%) 13 (56.5%) 6 (26.1%) 17 (73.9%) 15 (60%) 10 (40%)
51 to 55 years 6 (54.5%) 5 (45.5%) 6 (54.5%) 5 (45.5%) 6 (54.5%) 5 (45.5%) 7 (63.6%) 4 (36.4%)
≥ 56 years 2 (100%) 0 (0%) 1 (33.3%) 2 (66.7%) 3 (100%) 0 (0%) 2(66.7%) 1 (33.3%)
Breast feeding duration 0.97 0.04 0.78 0.93
0 month 7 (50%) 7 (50%) 5 (38.5%) 8 (61.5%) 8 (57.1%) 6 (42.9%) 7 (50%) 7 (50%)
1 to 30 months 11 (57.9%) 8 (42.1%) 14 (73.7%) 5 (26.3%) 8 (42.1%) 11 (57.9%) 9 (45%) 11 (55%)
31 to 60 months 12 (52.2%) 11 (47.8%) 11 (50%) 11 (50%) 13 (56.5%) 10 (43.5%) 12 (52.2%) 11 (47.8%)
61 to 120 months 10 (52.6%) 9 (47.4%) 6 (30%) 14 (70%) 10 (52.6%) 9 (47.4%) 11 (55%) 9 (45%)
Hormone replacement therapy 0.06 0.2 0.22 0.36
No 38 (57.6%) 28 (42.4%) 34 (51.5%) 32 (48.5%) 36 (54.5%) 30 (45.5%) 34 (50%) 34 (50%)
Yes 3 (25%) 9 (75%) 3 (27.3%) 8 (72.7%) 4 (33.3%) 8 (66.7%) 8 (66.7%) 4 (33.3%)
Table 6. The results of association analysis between expression of genes and patients’ data (Up/down regulation 
of genes was described according to the relative quantities of each gene in malignant tissue compared with the 
paired ANCT).
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of cancer leading to an augmented dependence or association presumably similar to what has been called as 
oncogene-addiction. However, further experiments are needed to verify this speculation.
Conclusion
In brief, in the present study, we introduced an in silico method for identification of MAPK14-related lncRNAs 
with putative ceRNA role in breast cancer and assessed expression of these lncRNAs in breast cancer tissues and 
ANCTs. Our data supports associations between expression levels of these lncRNAs and some clinical features. 
Future studies are needed to elaborate the underlying mechanisms of such observations. The identified interac-
tome comprising of MAPK14 and the 4 lncRNAs might provide new insight about the role of MAPK14 in the 
breast carcinogenesis and provide therapeutic targets for this cancer. As a future perspective, we can deepen the 
role of miRNAs in the mentioned network and assess the contribution of the selected miRNAs and their targets 
in the MAPK14-mediated breast carcinogenesis. Such studies would increase the insights about the regulatory 
mechanisms among mRNAs, lncRNAs, and miRNAs and identify promising biomarkers for breast cancer detec-
tion and treatment. Finally, this work deals with the transcriptome expression profile of MAPK14 and its associ-
ated lncRNAs. However, the effect of this interactome of MAPK14 and other interactors at the protein level were 
not assessed in this study which is a clear limitation of the present work.
Figure 4. Representative results of lncRNAs down/up regulation in association with clinical parameters.
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List of abbreviations. lncRNA (long non-coding RNA), ceRNA (competing endogenous RNA), MAP 
kinase (Mitogen-activated protein kinase), ANCT (adjacent non-cancerous tissue).
Ethics approval and consent to participate. The study protocol was approved by the Ethical Committee 
of Shahid Beheshti University of Medical Sciences. All patients signed informed consent forms. All steps were 
performed according to ethical guidelines.
NORAD P value HCG11 P value ZNRD1ASP P value MAPK14 P value
ER status
ER( + ) vs. ER(-) 0.14 (0.5) vs. 0.16 (0.5) 0.89
0.007 (0.02) vs. 
0.002 (0.002) 0.52
0.008 (0.03) vs. 
0.004 (0.009) 0.63
0.2 (0.6) vs. 0.1 
(0.22) 0.51
PR status
PR( + ) vs. PR(-) 0.15 (0.5) vs. 0.14 (0.46) 0.99
0.007 (0.03) vs. 
0.002 (0.003) 0.45
0.008 (0.03) vs. 
0.004 (0.009) 0.63
0.3 (0.63) vs. 0.1 
(0.2) 0.43
HER2 status
HER2 ( + ) vs. HER2 
(-)
0.03 (0.06) vs. 
0.17 (0.55) 0.34
0.003 (0.004) vs. 
0.007 (0.03) 0.68
0.001 (0.001) vs. 
0.008 (0.03) 0.46
0.12 (0.22) vs. 
0.2 (0.6) 0.6
Tumor grade
Grade 1 vs. 2 0.13 (0.22) vs. 0.18 (0.65) 0.94
0.004 (0.007) vs. 
0.01 (0.03) 0.8
0.004 (0.004) vs. 
0.01 (0.04) 0.72
0.54 (1.05) vs. 
0.07 (0.15) 0.02
Grade 1 vs. 3 0.13 (0.22) vs. 0.09 (0.27) 0.98
0.004 (0.007) vs. 
0.002 (0.002) 0.97
0.004 (0.004) vs. 
0.002 (0.002) 0.97
0.54 (1.05) vs. 
0.21 (0.54) 0.2
Grade 2 vs. 3 0.18 (0.65) vs. 0.09 (0.27) 0.79
0.01 (0.03)vs. 
0.002 (0.002) 0.58
0.01 (0.04) vs. 0.002 
(0.002) 0.47
0.07 (0.15) vs. 
0.21 (0.54) 0.59
Table 7. Comparison of expression levels of genes among distinct categories of tumor tissues.
Figure 5. Correlation between expressions of lncRNAs in tumoral tissues and ANCTs.
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Data availability
The datasets used and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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